Brief: Iovance Biotherapeutics Announces Clinical Program Update For Ln-145 In Non-Small Cell Lung Cancer

Iovance Biotherapeutics

27/12/2023 12:16

Dec 27 (Reuters) - Iovance Biotherapeutics Inc  IOVA.O :
    * IOVANCE BIOTHERAPEUTICS ANNOUNCES CLINICAL PROGRAM UPDATE
FOR
LN-145 IN NON-SMALL CELL LUNG CANCER
    * FDA PLACED A CLINICAL HOLD ON IOV-LUN-202 TRIAL ON
DECEMBER 22,
2023
    * BLA REMAINS ON TRACK TOWARD PRESCRIPTION DRUG USER FEE ACT
(PDUFA) ACTION DATE OF FEBRUARY 24, 2024
    * WILL PAUSE ENROLLMENT AND LN-145 TIL TREATMENT REGIMEN FOR
NEW
PATIENTS IN IOV-LUN-202 DURING CLINICAL HOLD
    * CLINICAL HOLD FOR IOV-LUN-202 HAS NO IMPACT ON ANY OTHER
IOVANCE
CLINICAL TRIALS
    * PATIENTS PREVIOUSLY TREATED WITH LN-145 IN IOV-LUN-202
TRIAL
WILL CONTINUE TO BE MONITORED & FOLLOWED ACCORDING TO PROTOCOL
    * PATIENTS WHO ALREADY UNDERGONE TUMOR RESECTION TO CONTINUE
TO
GET LN-145 TIL TREATMENT REGIMEN WITH ADDITIONAL PRECAUTIONS,
RISK MITIGATIONS

Source text for Eikon:  ID:nGNX2XsN5b 
Further company coverage:  IOVA.O 

 ((Reuters.Briefs@thomsonreuters.com;))